Leila Alland Biography and Net Worth

Director of Abeona Therapeutics

Dr. Alland, a pediatric hematologist-oncologist and accomplished physician-scientist, has been working in the biopharmaceutical industry since 2001 to bring novel therapies to patients. Dr. Alland is currently Chief Medical Officer of PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants. Previously, Dr. Alland served as Chief Medical Officer at Affimed, and prior to that she held the same position at Tarveda Therapeutics. Dr. Alland also held leadership positions at AstraZeneca, Bristol-Myers Squibb, Novartis, and Schering-Plough, where she worked on a broad range of oncology products from early to late-stage development and contributed to multiple successful drug approvals.

Dr. Alland obtained her medical degree from New York University School of Medicine, and her B.A. in Biology from the University of Pennsylvania. She completed her residency in Pediatrics at The Children’s Hospital of Philadelphia, and her fellowship in Pediatric Hematology/Oncology at The New York Hospital and Memorial Sloan-Kettering Cancer Center. Earlier in her career, Dr. Alland served as Assistant Professor of Pediatrics at Albert Einstein College of Medicine, where she was awarded the James S. McDonnell Foundation Scholar Award and pursued basic cancer research while also caring for children with cancer and blood disorders. Since 2020, Dr. Alland has served on the Board of Directors of Cytovia Therapeutics, Inc., an immuno-oncology company developing engineered cellular and antibody therapies to treat cancer. Dr. Alland is a member of the Scientific Advisory Council of Columbia University's Center for Radiological Research and serves as a scientific reviewer for the Cancer Prevention and Research Institute of Texas.

What is Leila Alland's net worth?: The estimated net worth of Leila Alland is at least $881.96 thousand as of February 2nd, 2026. Alland owns 173,614 shares of Abeona Therapeutics stock worth more than $881,959 as of February 4th. This net worth approximation does not reflect any other assets that Alland may own. Learn More about Leila Alland's net worth.
How do I contact Leila Alland?: The corporate mailing address for Alland and other Abeona Therapeutics executives is 3333 LEE PARKWAY SUITE 600, DALLAS TX, 75219. Abeona Therapeutics can also be reached via phone at 214-665-9495 and via email at [email protected]. Learn More on Leila Alland's contact information.
Has Leila Alland been buying or selling shares of Abeona Therapeutics?: During the last quarter, Leila Alland has sold $91,950.85 in Abeona Therapeutics stock. Most recently, Leila Alland sold 18,065 shares of the business's stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $5.09, for a transaction totalling $91,950.85. Following the completion of the sale, the director now directly owns 173,614 shares of the company's stock, valued at $883,695.26. Learn More on Leila Alland's trading history.
Who are Abeona Therapeutics' active insiders?: Abeona Therapeutics' insider roster includes Leila Alland (Director), Mark Alvino (Director), Michael Amoroso (CEO), Edward Carr (CAO), Faith Charles (Director), Brendan O'Malley (SVP), Vishwas Seshadri (CEO), Christine Silverstein (Director), Joseph Vazzano (CFO), and Todd Wider (Director). Learn More on Abeona Therapeutics' active insiders.
Are insiders buying or selling shares of Abeona Therapeutics?: During the last twelve months, insiders at the biopharmaceutical company sold shares 30 times. They sold a total of 552,843 shares worth more than $3,107,097.61. The most recent insider tranaction occured on February, 2nd when Director Leila Alland sold 18,065 shares worth more than $91,950.85. Insiders at Abeona Therapeutics own 6.9% of the company. Learn More about insider trades at Abeona Therapeutics.
Information on this page was last updated on 2/2/2026.

Leila Alland Insider Trading History at Abeona Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/2/2026	Sell	18,065	$5.09	$91,950.85	173,614
5/16/2024	Buy	11,000	$4.71	$51,810.00	82,857

Leila Alland Buying and Selling Activity at Abeona Therapeutics

Abeona Therapeutics Company Overview

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Today's Range

Now: $5.08

$5.01

$5.30

50 Day Range

MA: $5.17

$4.55

$5.52

2 Week Range

Now: $5.08

$3.93

$7.54

Volume

1,152,880 shs

Average Volume

1,208,244 shs

Market Capitalization

$275.29 million

P/E Ratio

4.13

Dividend Yield

N/A

Beta

1.18